Market
Scenario:
Global
cell Viability Assays market is expected to grow significantly over the
forecast period. It is estimated that the global cell Viability Assays market
is expected to register a CAGR ~ 9.2% during the forecast period of 2018–2023.
Cell-based assays are techniques used for the screening collections of
compounds to find out if the test molecules have any effect on cell
proliferation or show direct cytotoxic effects that eventually lead to cell
death. The measurement of cell viability plays a significant role in all forms
of cell culture. The main application of cell viability is to determine whether
the cells are alive. For instance, in cancer research, cell viability assays
are used to confirm the killing of tumor cells and to verify the survival of normal
cells.
Numerous factors such as growing prevalence of chronic and infectious
diseases, growing availability of funds for cell-based research, rising need of
cell-based assays in research and development activities are expected to drive
the growth of the market. For instance, in 2015, the National Institutes of
Health invested around 1,429 million USD for stem cells research. Moreover,
increasing focus on developing cell-based therapeutics boosts the growth of the
market. However, the rising cost of the instruments may hamper the market
growth during the assessment period.
Key
Players
- Thermo Fisher Scientific
- Merck KGaA
- Bio-Rad Laboratories
- G E Healthcare
- Danaher Corporation
- Becton, Dickinson and Company
- Promega Corporation
- Biotium
- Abcam plc
- Creative Bioarray
- Biotek Instruments
- PerkinElmer
Segmentation
The
market has been segmented into products, cell type, applications, and end-user.
The
market, on the basis of products, has been segmented into consumables and
instruments.
The
consumables segment has been further divided into reagents, assay kits, and
microplates. The Assay kits segment has been further segmented into tetrazolium
reduction assay kits, resazurin cell Viability Assays kits, calcein-Am cell
Viability Assays kits and other assay kits. Furthermore, tetrazolium assay kits
have been classified into MIT assay kits and other tetrazolium assay kits.
The
instruments have been segmented into automated cell counters, flow cytometers,
spectrophotometers, and cell imaging & analysis systems.
The
market, by cell type, has been segmented into human cells, microbial cells, and
animal cells.
The market,
by applications, has been segmented into stem cell research, clinical &
diagnostic applications, drug discovery & development, and others.
The
market, by end-user, has been segmented into pharmaceutical & biotechnology
companies, academic & research institutes, hospital & diagnostic
laboratories and others.
The
European cell Viability Assays market has been segmented into Western Europe
and Eastern Europe. Western Europe has further been classified as Germany,
France, the UK, Italy, Spain, and the rest of Western Europe.
The cell
Viability Assays market in Asia-Pacific has been segmented into Japan, China,
India, South Korea, Australia, and the rest of Asia-Pacific. The cell Viability
Assays market in the Middle East & Africa has been segmented into the
Middle East and Africa.
The
market has been segmented, by region, into the Americas, Europe, Asia-Pacific,
and the Middle East & Africa. The cell Viability Assays market in the
Americas has further been segmented into North America and South America, with
the North American market divided into the US and Canada.
Regional
Market Summary
Geographically,
the Americas is anticipated to dominate the global cell Viability Assays market
owing to a well-developed healthcare sector, rising prevalence of infectious and
chronic diseases and growing healthcare expenditure. According to an article
published by the Centers for Medicare and Medicaid Services in August 2018, the
US healthcare spending had reached USD 3.3 trillion in 2016. Europe is expected
to hold the second largest position in the global cell Viability Assays market.
The market growth in this region is attributed to the growing prevalence of
chronic diseases and increasing healthcare expenditure. According to a report
published by EU observer in September 2014, more than the one-third population
of Europe above the age of 15 years in suffering from a chronic disease and 2
in every 3 people reaching the age of retirement have at least 2 chronic
diseases.
Asia-Pacific
is anticipated to be the fastest growing region in the market due to the rising
number of stem cell, proteomics, and genomics research activities. Also,
increased expenditure in the healthcare sector is expected to boost the growth
in this market.
On the
other hand, the Middle East & Africa has the least share of the market.
Majority of the market of this region is expected to be held by the Middle East
region due to a well-developed healthcare sector and growing government
initiatives for the healthcare sector.
Detailed Table
of Contents:
Chapter 1. Report Prologue
Chapter 2. Market
Introduction
2.1 Definition
2.2 Scope Of The Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
Chapter 3. Research
Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
Chapter 4. Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
About US:
Market
Research Future (MRFR), enable customers to unravel the complexity of various
industries through Cooked Research Report (CRR), Half-Cooked Research Reports
(HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market
Research & Consulting Services.
Contact
Us:
Market
Research Future
Office
No. 528, Amanora Chambers
Magarpatta
Road, Hadapsar,
Pune
- 411028
Maharashtra,
India
Phone:
+1 646 845 9312
Email:
sales@marketresearchfuture.com